Bo-Chem Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.12 M
as on 24-10-2024
- Company Age 44 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.95 M
as on 24-10-2024
- Revenue 87.25%
(FY 2023)
- Profit -154.88%
(FY 2023)
- Ebitda -721.54%
(FY 2023)
- Net Worth -125.62%
(FY 2023)
- Total Assets 1.27%
(FY 2023)
About Bo-Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.12 M.
The company has closed loans amounting to ₹0.95 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ashit Mehta, Harsh Mehta, and Mangesh Revdekar serve as directors at the Company.
- CIN/LLPIN
U24100MH1980PTC022617
- Company No.
022617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 May 1980
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Bo-Chem?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashit Mehta  | Director | 01-Apr-2010 | Current |
| Harsh Mehta | Director | 27-Nov-2010 | Current |
| Mangesh Revdekar | Director | 28-Mar-2018 | Current |
Financial Performance of Bo-Chem.
Bo-Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 87.25% increase. The company also saw a substantial fall in profitability, with a 154.88% decrease in profit. The company's net worth observed a substantial decline by a decrease of 125.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bo-Chem?
In 2023, Bo-Chem had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sunrise Auxichem Private LimitedActive 17 years 3 months
Ashit Mehta and Harsh Mehta are mutual person
Charges (Loans)
₹0
₹0.95 M
Charges Breakdown by Lending Institutions
- Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 1984 | Bank Of India | ₹0.40 M | Satisfied |
| 22 Sep 1981 | Bank Of India | ₹0.27 M | Satisfied |
| 07 Sep 1981 | Bank Of India | ₹0.10 M | Satisfied |
| 24 Sep 1980 | Bank Of India | ₹0.19 M | Satisfied |
How Many Employees Work at Bo-Chem?
Unlock and access historical data on people associated with Bo-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bo-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bo-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
